Orgenesis Inc. (NASDAQ:ORGS – Get Free Report)’s share price traded up 132.5% during mid-day trading on Friday . The stock traded as high as $0.3720 and last traded at $0.3720. 213 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 1,098 shares. The stock had previously closed at $0.16.
Orgenesis Stock Performance
The firm has a market capitalization of $1.92 million, a P/E ratio of -0.03 and a beta of 3.14. The stock’s 50 day simple moving average is $0.38 and its 200 day simple moving average is $0.38.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Featured Stories
- Five stocks we like better than Orgenesis
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
